USPTO serial 99866606
DRAGEN STRATAMAP
Reviewed by CopyMark Law Group
Status 641Office Action
- Filing date
- Status date
- Registration date
- —
- Examiner
- BROWNE, LUCY E
- Law office
- TMO LAW OFFICE 125
What this means
The USPTO has issued an Office Action on this application. A response is typically required before the deadline, or the application can be abandoned.
Need help with DRAGEN STRATAMAP?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Office Action, set up monitoring, or talk with CopyMark.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
San Diego, CA, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Katherine McMorrow
Katherine McMorrow Baker & Hostetler LLP1900 Avenue of the Stars, Suite 2700Los Angeles, CA 90067United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 042 | Software as a service (SaaS) services and platform as a service (PaaS) services featuring software for collecting, storing, accessing, processing, analyzing, manipulating, visualizing, sharing, and reporting biological, genetic, genomic, protein, multi-omic, transcriptomic, clinical, medical, diagnostic, nucleic acid, and next-generation sequencing (NGS) data and information; Providing non-downloadable computer software for collecting, storing, accessing, processing, analyzing, reporting, visualizing, storing, sharing, and manipulating genetic, genomic, protein, multi-omics, transcriptomic, clinical, medical, diagnostic, nucleic acid, and next-generation sequencing (NGS) data and information; Software as a service (SaaS) services and platform as a service (PaaS) services featuring software for use with diagnostics, medical treatment, medical research, medical forensics, laboratory medicine, genetic testing, nucleic acid sequencing, protein sequencing, genetics, genotyping, life sciences, agriculture, food safety, cosmetics, dermatology, drug development, pharmaceutical research, dietary supplement research, dental research, clinical research, fungicide research, herbicide research, multi-omics, spatial transcriptomics, prenatal screening and testing, diseases, forensics, in vitro diagnostics, infectious diseases, reproductive health, neonatal intensive care, personalized medicine, microbiology, biology, biotechnology, metagenomics, and disease treatment; Software as a service (SaaS) and platform as a service (PaaS) services featuring software for use in the fields of diagnostics, medical treatment, medical research, medical forensics, laboratory medicine, genetic testing, nucleic acid sequencing, protein sequencing, genetics, genotyping, life sciences, agriculture, food safety, cosmetics, dermatology, drug development, pharmaceutical research, dietary supplement research, dental research, clinical research, fungicide research, herbicide research, multi-omics, spatial transcriptomics, prenatal screening and testing, diseases, forensics, in vitro diagnostics, infectious diseases, reproductive health, neonatal intensive care, personalized medicine, microbiology, biology, biotechnology, metagenomics, and disease treatment; Providing non-downloadable computer software for analysis of nucleic acid sequencing, protein sequencing, multi-omics, transcriptomic, genotyping, genetic testing, genetics, molecular, and biomarker data; Providing non-downloadable software for use in genetic sequencer integration; Software as a service (SaaS) and Platform as a service (PaaS) services featuring software for enabling genetic analysis, genomic analysis, multi-omics analysis, transcriptomic analysis, protein analysis, and molecular analysis; Software as a service (SaaS) services and platform as a service (PaaS) services featuring software for accessing, researching, analyzing, and interacting with integrated genetic data, genomic data, multi-omics data, transcriptomic data, protein data, molecular data, medical data, biomedical data, clinical data, and biomarker data; Application service provider (ASP) featuring software for providing access to multiple databases that contain aggregated results of genotyping and genetic, genomic, protein, multi-omics, transcriptomic, molecular, and biomarker data; Providing non-downloadable computer software for storage, organization, processing, retrieval, analysis, and output of sampling and testing information in the fields of diagnostics, medical treatment, medical research, medical forensics, laboratory medicine, genetic testing, nucleic acid sequencing, protein sequencing, genetics, genotyping, life sciences, agriculture, food safety, cosmetics, dermatology, drug development, pharmaceutical research, dietary supplement research, dental research, clinical research, fungicide research, herbicide research, multi-omics, spatial transcriptomics, prenatal screening and testing, diseases, forensics, in vitro diagnostics, infectious diseases, reproductive health, neonatal intensive care, personalized medicine, microbiology, biology, biotechnology, metagenomics, and disease treatment | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 23, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 23, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 23, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 13, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 9, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 4, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jun 4, 2026 | NWAP | NEW APPLICATION ENTERED | — |